Valeant Pharmaceuticals International, Inc. Press Releases

VRX 
$118.21
*  
0.82
0.7%
Get VRX Alerts
*Delayed - data as of Aug. 1, 2014  -  Find a broker to begin trading VRX now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    VRX After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit
8/1/2014 3:01:00 PM - PR Newswire

Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results
7/31/2014 6:00:00 AM - PR Newswire

Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements
7/24/2014 8:00:00 AM - PR Newswire

Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements
7/21/2014 7:13:00 AM - PR Newswire

Valeant Pharmaceuticals Files Investor Presentation
7/18/2014 8:00:00 AM - PR Newswire

Bausch + Lomb's VICTUS® Femtosecond Laser Platform Receives 510(k) Clearance from FDA for Lens Fragmentation Procedure
7/17/2014 8:00:00 AM - PR Newswire

Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan
7/14/2014 8:00:00 AM - PR Newswire

Galderma Finalizes Major Expansion in Aesthetic and Corrective Dermatology in the U.S. and Canada
7/10/2014 10:59:00 AM - PR Newswire

Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma
7/10/2014 9:30:00 AM - PR Newswire

Valeant Pharmaceuticals Completes Acquisition Of PreCision Dermatology
7/8/2014 8:00:00 AM - PR Newswire

RBCC Developing New Tech to Help Prevent Deaths From Prescription Overdoses
7/2/2014 5:00:00 AM - Business Wire

Valeant Files Preliminary Proxy Statement for Special Meeting of Shareholders to Approve Share Issuance in Proposed Acquisition of Allergan
6/25/2014 8:00:00 AM - PR Newswire

Valeant Posts Fact-Based Answers To Refute Allergan's Misleading Statements
6/23/2014 8:00:00 AM - PR Newswire

Akorn Divests ECR Pharmaceuticals to Valeant
6/20/2014 11:11:00 AM - Business Wire

Valeant Commences Exchange Offer For Allergan
6/18/2014 9:29:00 AM - PR Newswire

Valeant Pharmaceuticals Receives U.S. FDA Clearance For Restylane® Silk
6/16/2014 8:45:00 AM - PR Newswire

Valeant Pharmaceuticals Announces Planned Management Departure
6/13/2014 8:46:00 PM - PR Newswire

Valeant Pharmaceuticals To Hold Conference Call On Tuesday, June 17, 2014 To Correct Recent Misrepresentations
6/13/2014 12:01:00 PM - PR Newswire

Pershing Square Files Lawsuit in Delaware Court of Chancery Seeking Confirmation that Allergan’s Rights Plan Is Not Triggered by Efforts to Call a Special Meeting
6/13/2014 6:00:00 AM - Business Wire

Technical Pulse on Pharma Stocks -- Research on Valeant Pharma Intl., Acura Pharma, Teva Pharma Industries, and Lannett
6/11/2014 7:20:00 AM - PR Newswire

RBCC to Expand Market for 'Underused' Addiction Treatment With New Technology
6/11/2014 5:00:00 AM - Business Wire

Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosis
6/9/2014 5:00:00 AM - PR Newswire

Valeant And Pershing Square Make Revised Offer For Allergan Contingent On Good Faith Negotiations
5/30/2014 2:36:00 PM - PR Newswire

Galderma to gain rights to Restylane, Perlane, Sculptra and Dysport in the United States and Canada
5/28/2014 12:21:00 PM - PR Newswire

Valeant Substantially Increases Merger Proposal For Allergan
5/28/2014 6:00:00 AM - PR Newswire